Table 1.
The proportion of COVID-19 patients with pulmonary fibrosis at discharge and its relationship to the clinical classification.
Table 2.
The type of lesions and the affected lung segments in 239 COVID-19 patients with pulmonary fibrosis at discharge.
Fig 1.
A. The AI inflammation scores of 239 COVID-19 patients with pulmonary fibrosis at discharge. *, P<0.05; **, P<0.01; B. Comparison of the AI inflammation score or pulmonary fibrosis score between patients at discharge and 30 days (n = 34 patients), 60 days (n = 11 patients) and 90 days (n = 7 patients) after discharge. C. Comparison of chest HRCT results between patients at discharge and 30 days after hospital discharge. a, b and c represent three separate patients: a represents a patient with mild pulmonary fibrosis, b represents a patient with moderate pulmonary fibrosis, and c represents a patient with severe pulmonary fibrosis. ① represents the chest HRCT at discharge; ② represents the extent of lesions marked by AI at discharge (red); ③ represents the chest HRCT 30 days after hospital discharge; ④ represents the extent of lesions marked by AI 30 days after hospital discharge (red).
Table 3.
The clinical characteristics of COVID-19 patients with pulmonary fibrosis at discharge.
Table 4.
Analysis of risk factors in patients with pulmonary fibrosis.
Table 5.
The prognosis of patients with pulmonary fibrosis.